FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Dunne Michael W.					2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ ITRM ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 09/07/2022									Officer (g below)	jive title		Other (specify below)		
C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE					4. If Amendment, Date of Original Filed (Month/Day/Year) 09/09/2022							6. Indiv	dividual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) DUBLIN 2 (City)	L2 (State)	(Zi	p)												Form file	d by More	than C	ne Reportin	g Person
		Та	ble I - No	n-Deri	ivativ	e Se	curitie	s Acq	uired, l	Disp	osed of,	, or Be	enefic	ially Ow	ned				
Date				e Inth/Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)					curities Acquired (A) or ssed Of (D) (Instr. 3, 4 a			Following	urities neficially Owned lowing Reported		nership : Direct (D) lirect (I) . 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A (D	A) or D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Ordinary Shares															35,575(1)(2)			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity (Instr. 3) or Exercise (Month/Day/Year) if any			ate,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable an Expiration Date (Month/Day/Year)		te	7. Title and Am Securities Und Derivative Secu (Instr. 3 and 4)		erlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(	e s lly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V		(A)	(D)			Expiration Date	Title		Amount or Number of Shares		(Instr. 4)			

## **Explanation of Responses:**

- 1. On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.
- 2. This amendment is being filed to address an error due to rounding when calculating the reverse share split. The Amount of Securities Beneficially Owned Following Reported Transaction on September 7, 2022, which were reported as 35,576, should have been reported as 35,575. The extra share was also inadvertently included in the reporting person's Form 4 filed on January 4, 2023.

## Remarks:

/s/ Michael W. Dunne 02/27/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.